Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
4(100.0%)
4Total
N/A(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03272984Not ApplicableCompleted

ERAS for Patients Received Neoadjuvant Chemotherapy

Role: lead

NCT03238404Not ApplicableCompleted

Neoadjuvant Chemotherapy for Patients With Advanced Gastric Cancer in ERAS Programs for Radical Gastrectomy

Role: lead

NCT03238820Not ApplicableCompleted

Robotic Resection for Patients With Gastric Gastrointestinal Stromal Tumors: a Single-center Study

Role: lead

NCT03236051Not ApplicableUnknown

Multimodal Analgesia in Laparoscopic Radical Gastrectomy With Gastric Cancer: a Multi-center Study

Role: lead

All 4 trials loaded